HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Not On Vacation: Warning Letter Burst Targets More Skin-Care Marketers

This article was originally published in The Rose Sheet

Executive Summary

“Brightening” product claims continue to be flagged by FDA in warning letters, as well as statements about collagen production, cell regeneration and treatment of skin diseases. Medik8 marketer Ageless Aesthetics, Annemarie Gianni Skin Care and Be Green Bath & Body Founder Karen Roche are the latest warning recipients.

You may also be interested in...

FDA Warning Letters Target Skin Brighteners, Muscle-Relaxing Claims

Agency recently posted three warning letters issued to skin-care marketers in August for unapproved drug claims, including statements about reducing muscle contractions for anti-aging effects. All three warnings included a skin-brightening product among items identified as non-compliant on the basis of their claims.

FDA Warning Letter Barrage Continues With Five More To Close July

At least nine skin-care marketers received FDA warning letters in July for unapproved drug claims. In the month’s final two weeks, recipients included companies behind the Freeze 24-7 Instant Targeted Wrinkle Treatment and a Resurgent Stem Cell Firming Activator, among others.

FDA Warning Streak Continues, Underscoring Risky Products And Claims

Agency has been turning up the heat this summer on skin-care marketers, posting two more July warning letters issued to companies for use of unapproved drug claims. Firms that sell anti-aging serums, eye-area formulas or anything promoted as an “anti-wrinkle” solution should review their claims to ensure compliance.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts